Mutations in HIV‐1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverse‐Transcriptase Inhibitors: Effect on Response to Efavirenz‐Based Therapy in an Urban Observational Cohort - Concepedia

Concepedia

Publication | Open Access

Mutations in HIV‐1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverse‐Transcriptase Inhibitors: Effect on Response to Efavirenz‐Based Therapy in an Urban Observational Cohort

DOI Full Paper Access

35

Citations

18

References

2004

Year

Valerio Tozzi, Mauro Zaccarelli, Pasquale Narciso, Maria Paola Trotta, Francesca Ceccherini‐Silberstein, Patrizio De Longis, Giampiero D’Offizi, Federica Forbici, Roberta D’Arrigo, Evangelo Boumis,

The Journal of Infectious Diseases

Abstract

The M41L, M184V, L210W, and T215Y mutations were associated with a better, although transient, virological outcome in patients treated with efavirenz-based regimens.

References

	Year	Citations
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents Annals of Internal Medicine	1998	5.2K
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Bruno Ledergerber, Matthias Egger, Milos Opravil, The Lancet Treatment And PreventionNeurovirologyHuman RetrovirusActive Antiretroviral TherapyHiv-1 Patients	1999	933
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions Gregory M. Lucas, Richard E. Chaisson, Richard D. Moore Annals of Internal Medicine	1999	853
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial J. Durant, Philippe Clevenbergh, Philippe Halfon, The Lancet Health SciencesTreatment And PreventionHuman RetrovirusPharmacologyClinical Trials	1999	761
Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors Rebecca Spence, Warren M. Kati, Karen S. Anderson, Science	1995	521
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy John D. Baxter, Douglas L. Mayers, Deborah Wentworth, AIDS	2000	502
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial Cristina Tural, Christopher Holtzer, Jonathan Schapiro, AIDS	2002	312
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) Antonella Cingolani, Andrea Antinori, Maria Gabriella Rizzo, AIDS	2002	215
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection Martin Hirsch JAMA Adult Hiv-1 InfectionHealth SciencesTreatment And PreventionHuman RetrovirusDrug Testing	2000	208
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting The EuroGuidelines Group for HIV Resistance AIDS European SettingLaboratory GuidelinesPharmacotherapyAntiviral DrugDrug Resistance	2001	183

Page 1